Sino Biopharmaceutical Future Growth

Future criteria checks 3/6

Sino Biopharmaceutical is forecast to grow earnings and revenue by 12.9% and 9% per annum respectively. EPS is expected to grow by 13% per annum. Return on equity is forecast to be 9.2% in 3 years.

Key information

12.9%

Earnings growth rate

13.0%

EPS growth rate

Pharmaceuticals earnings growth	10.9%
Revenue growth rate	9.0%
Future return on equity	9.2%
Analyst coverage	Good
Last updated	25 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

SZSC:1177 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	36,324	3,661	5,956	8,467	21
12/31/2025	32,728	3,207	6,118	7,736	25
12/31/2024	29,564	3,462	5,280	7,120	25
6/30/2024	27,790	2,142	5,345	6,473	N/A
3/31/2024	26,995	1,995	4,968	6,269	N/A
12/31/2023	26,199	1,847	4,591	6,066	N/A
6/30/2023	25,116	1,254	3,314	4,987	N/A
3/31/2023	25,571	1,656	4,017	5,626	N/A
12/31/2022	26,026	2,059	4,719	6,265	N/A
9/30/2022	28,241	5,296	4,895	6,622	N/A
6/30/2022	27,701	8,049	5,071	6,980	N/A
3/31/2022	27,215	13,655	N/A	N/A	N/A
12/31/2021	26,861	14,608	3,499	5,366	N/A
9/30/2021	26,129	12,465	N/A	N/A	N/A
6/30/2021	25,353	10,011	4,337	6,105	N/A
3/31/2021	24,668	3,809	N/A	N/A	N/A
12/31/2020	23,647	2,771	3,537	5,325	N/A
9/30/2020	23,039	2,302	N/A	N/A	N/A
6/30/2020	24,354	2,558	1,827	3,373	N/A
3/31/2020	24,248	2,781	N/A	N/A	N/A
12/31/2019	24,234	2,762	3,622	5,325	N/A
9/30/2019	24,479	9,101	N/A	N/A	N/A
6/30/2019	23,691	9,125	4,774	6,543	N/A
3/31/2019	22,444	9,132	N/A	N/A	N/A
12/31/2018	20,889	9,046	3,417	5,094	N/A
9/30/2018	19,103	2,567	N/A	N/A	N/A
6/30/2018	17,062	2,436	1,231	2,572	N/A
3/31/2018	15,609	2,363	N/A	N/A	N/A
12/31/2017	14,819	2,171	N/A	3,733	N/A
9/30/2017	14,491	2,115	N/A	N/A	N/A
6/30/2017	14,258	1,862	N/A	4,773	N/A
3/31/2017	13,899	1,789	N/A	N/A	N/A
12/31/2016	13,543	1,637	N/A	2,995	N/A
9/30/2016	13,271	1,674	N/A	N/A	N/A
6/30/2016	12,858	1,604	N/A	1,757	N/A
3/31/2016	12,507	1,575	N/A	N/A	N/A
12/31/2015	12,189	1,490	N/A	1,919	N/A
9/30/2015	12,030	1,432	N/A	N/A	N/A
6/30/2015	11,124	1,447	N/A	1,973	N/A
3/31/2015	10,552	1,263	N/A	N/A	N/A
12/31/2014	9,900	1,210	N/A	1,840	N/A
9/30/2014	9,205	1,074	N/A	N/A	N/A
6/30/2014	8,876	951	N/A	2,000	N/A
3/31/2014	8,434	886	N/A	N/A	N/A
12/31/2013	7,731	809	N/A	1,230	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1177's forecast earnings growth (12.9% per year) is above the savings rate (2.3%).

Earnings vs Market: 1177's earnings (12.9% per year) are forecast to grow faster than the Hong Kong market (11.6% per year).

High Growth Earnings: 1177's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1177's revenue (9% per year) is forecast to grow faster than the Hong Kong market (7.8% per year).

High Growth Revenue: 1177's revenue (9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 1177's Return on Equity is forecast to be low in 3 years time (9.2%).

Sino Biopharmaceutical Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Recent updates

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold HK$51m worth of stock

First half 2024 earnings released: EPS: CN¥0.077 (vs CN¥0.06 in 1H 2023)

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.11 in FY 2022)

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings released: EPS: CN¥0.10 (vs CN¥0.14 in FY 2022)

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Full year 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.78 in FY 2021)

Sino Biopharmaceutical Limited Announces Clinical Trial Application of Innovative Medicine "Tqb2103 (Claudin18.2 ADC)" Accepted by Center for Drug Evaluation

Sino Biopharmaceutical Limited Announces Application for Marketing of Category I Innovative Drug Tqb2450 Injection in Combination with Anlotinib Hydrochloride Capsules for the Indication of First-Line Treatment of Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces the Enrollment of All Patients in Phase III Clinical Trial of "Tqg203"

Less than half of directors are independent

Sino Biopharmaceutical Limited Provides Revenue Guidance for 2023

Upcoming dividend of HK$0.06 per share

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the period ended 30 June 2022, Payable on 28 September 2022

First half 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.45 in 1H 2021)

Sino Biopharmaceutical Limited to Report First Half, 2022 Results on Aug 23, 2022

Sino Biopharmaceutical Limited Announces CEO Changes, Effective July 28, 2022

Sino Biopharmaceutical Limited Announces Application for Marketing of Category 1 Anti-Tumor Innovative Drug TQ-B3101 Capsule

Sino Biopharmaceutical Limited Announces Approval of Category 1 Innovative Drug TQC2938 Injection for Clinical Trial

Upcoming dividend of HK$0.04 per share

Sino Biopharmaceutical Submits Application for Marketing of the Category I Anti-Tumor Innovative Drug "TQ-B3139"

Full year 2021 earnings released: EPS: CN¥0.78 (vs CN¥0.15 in FY 2020)

Sino Biopharmaceutical Limited's Category I Anti-Tumor Innovative Drug "TQB2930" Obtained Approval for Clinical Trial

Sino Biopharmaceutical Limited Announces Anlotinib Hydrochloride Capsules Obtains Approval for the Fifth Indication

Sino Biopharmaceutical Limited Announces Innovative Drug "TQ-B3525" Was Included in the List of Breakthrough Therapy Drugs by CDE

Sino Biopharmaceutical Limited Announces That Application for Clinical Trial of "TQC2938" Injection, A Category I New Drug Self-Developed by the Group, Has Been Submitted to and Accepted by the National Medical Products Administration of China